Sergi Papiol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sergi Papiol has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Urs Heilbronner
Institute of Psychiatric Phenomics and Genomics, University Hospital, LMU Munich
36 shared publications Peter Falkai
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany; German Center for Mental Health (DZPG), partner site Munich/Augsburg, Germany; Max Planck Institute of Psychiatry, Munich, Germany
25 shared publications- Peter Falkai
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
24 shared publications - Thomas G. Schulze
Ludwig Maximilian University of Munich
21 shared publications Thomas G. Schulze
Institute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU Munich, Munich, Germany; German Center for Mental Health (DZPG), partner site Munich/Augsburg, Germany; Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
20 shared publications- Eva C. Schulte
Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Bonn, University of Bonn
17 shared publications
Latest Publications
- Open Access
Recalculated CNV penetrance: what it does and does not change for counselling
Goh et al. recently reported that most recurrent copy number variants (CNVs) are far less penetrant for intellectual disability (ID) than previously estimated, and recommended that fourteen should no longer be reported. We show that the lower estimates arise mainly from assuming the population prevalence of ID alone, while case counts derive from broad diagnostic referral cohorts in which about half of individuals were referred for other indications. The proposed formula estimates a risk difference rather than penetrance, and cases and controls were selected, assayed and phenotyped differently. Restricting the outcome to ID also leaves the analysis unable to inform risk for autism, epilepsy, psychiatric, cardiac and other phenotypes. We recommend that families receive phenotype-specific absolute risks for carriers alongside background risks, and that reporting decisions be made locus by locus by guideline bodies, considering all relevant phenotypes. The recalculated estimates inform this debate but are not yet sufficient grounds for changing reporting practice.
Open AccessRecalculated CNV penetrance: what it does and does not change for counselling
Goh et al. recently reported that most recurrent copy number variants (CNVs) are far less penetrant for intellectual disability (ID) than previously estimated, and recommended that fourteen should no longer be reported. We show that the lower estimates arise mainly from assuming the population prevalence of ID alone, while case counts derive from broad diagnostic referral cohorts in which about half of individuals were referred for other indications. The proposed formula estimates a risk difference rather than penetrance, and cases and controls were selected, assayed and phenotyped differently. Restricting the outcome to ID also leaves the analysis unable to inform risk for autism, epilepsy, psychiatric, cardiac and other phenotypes. We recommend that families receive phenotype-specific absolute risks for carriers alongside background risks, and that reporting decisions be made locus by locus by guideline bodies, considering all relevant phenotypes. The recalculated estimates inform this debate but are not yet sufficient grounds for changing reporting practice.
- Open Access
- 31 March 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Reliability and validity of the Kurdish version of the patient health questionnaire-15 in a trauma-affected population
Background: Somatic symptoms are common among trauma-exposed populations and are often associated with persistent distress and functional impairment, highlighting the need for culturally appropriate assessment tools. Objective: This study aimed to translate and culturally adapt the Patient Health Questionnaire-15 (PHQ-15), a screening measure of somatic symptom burden, into Central Kurdish and assess its psychometric properties among survivors of chemical gas exposure. Methods: A total of 534 survivors were recruited through community and registry sources. After translation and cultural adaptation, item 4 and item 11 were removed due to cultural and gender-specific considerations and limited psychometric performance, resulting in a 13-item version. Factor structure was examined using confirmatory factor analysis (CFA) and exploratory structural equation modeling (ESEM). Measurement invariance across gender and age groups was evaluated using multi-group CFA. Internal consistency was assessed using McDonald’s omega. An exploratory network analysis (EBICglasso) examined conditional associations among symptoms. Results: Both a unidimensional CFA model (CFI = 0.988, RMSEA = 0.054) and a three-factor ESEM model (CFI = 0.992, RMSEA = 0.046) showed good model fit, with the ESEM structure providing a more differentiated representation of pain/fatigue, gastrointestinal, and cardiopulmonary domains. Measurement invariance testing supported full scalar invariance across gender, while partial metric invariance was observed across age groups. Internal consistency was acceptable (ω = 0.70–0.83). Network estimates demonstrated acceptable stability, with correlation stability coefficients of 0.59 for edge strength and 0.52 for bridge strength, and should be interpreted as exploratory. Conclusion: The culturally adapted 13-item Kurdish PHQ demonstrates acceptable reliability and initial evidence of construct validity in trauma-exposed survivors of chemical attacks. The instrument may be used as a screening tool for somatic symptom burden in this context, while further validation in broader Kurdish populations is recommended.
- 31 March 2026
- Published by Springer Nature in BMC Psychiatry
- Vol. 26 (1)
Open AccessReliability and validity of the Kurdish version of the patient health questionnaire-15 in a trauma-affected population
Background: Somatic symptoms are common among trauma-exposed populations and are often associated with persistent distress and functional impairment, highlighting the need for culturally appropriate assessment tools. Objective: This study aimed to translate and culturally adapt the Patient Health Questionnaire-15 (PHQ-15), a screening measure of somatic symptom burden, into Central Kurdish and assess its psychometric properties among survivors of chemical gas exposure. Methods: A total of 534 survivors were recruited through community and registry sources. After translation and cultural adaptation, item 4 and item 11 were removed due to cultural and gender-specific considerations and limited psychometric performance, resulting in a 13-item version. Factor structure was examined using confirmatory factor analysis (CFA) and exploratory structural equation modeling (ESEM). Measurement invariance across gender and age groups was evaluated using multi-group CFA. Internal consistency was assessed using McDonald’s omega. An exploratory network analysis (EBICglasso) examined conditional associations among symptoms. Results: Both a unidimensional CFA model (CFI = 0.988, RMSEA = 0.054) and a three-factor ESEM model (CFI = 0.992, RMSEA = 0.046) showed good model fit, with the ESEM structure providing a more differentiated representation of pain/fatigue, gastrointestinal, and cardiopulmonary domains. Measurement invariance testing supported full scalar invariance across gender, while partial metric invariance was observed across age groups. Internal consistency was acceptable (ω = 0.70–0.83). Network estimates demonstrated acceptable stability, with correlation stability coefficients of 0.59 for edge strength and 0.52 for bridge strength, and should be interpreted as exploratory. Conclusion: The culturally adapted 13-item Kurdish PHQ demonstrates acceptable reliability and initial evidence of construct validity in trauma-exposed survivors of chemical attacks. The instrument may be used as a screening tool for somatic symptom burden in this context, while further validation in broader Kurdish populations is recommended.
- Open Access
- 13 March 2026
- Published by Springer Nature
- p. 389-399
Emil Kraepelin and Biological Research in Psychiatry Today
Emil Kraepelin introduced clinical and scientific methodology into psychiatry research and thus helped firmly establish psychiatry into medicine. There have been varying, good and bad times for people with mental illness and psychiatry since Kraepelin’s death. But the legacy of his textbook and research agenda has continued to be of central importance to psychiatry to the present day, and however underfunded, psychiatry has been pursuing state-of-the-art research on mental health and mental illness with a good visibility. Psychiatric research needs to focus on a better understanding of the aetiopathology of mental disorders, to develop (bio)-markers that characterise pathophysiologically distinct subgroups and to implement mechanistically informed treatments. This will be crucial to make precision psychiatry a clinical reality. To make significant progress, there is a need to address relevant pathophysiological questions as well as a need to form teams of research specialists dedicated to answering these pressing questions. Once diagnostic and treatment targets are identified, clinical studies from single-case studies to large-scale implementation randomised controlled trials (RCTs) can bring these targets from the laboratory to the clinic. The final goal is to develop innovative personalised treatment strategies with a particular focus on conditions that are currently treatment-resistant. These include cognitive impairments and the so-called negative symptoms including anhedonia, avolition and lack of drive. There is no need for a pessimistic assessment of the progress achieved in the last 100 years; however, excellent research, as well as serendipity, is required to ensure transformative innovations. Both positive and negative findings need to be published and sufficient funding secured.
- 13 March 2026
- Published by Springer Nature
- p. 389-399
Open AccessEmil Kraepelin and Biological Research in Psychiatry Today
Emil Kraepelin introduced clinical and scientific methodology into psychiatry research and thus helped firmly establish psychiatry into medicine. There have been varying, good and bad times for people with mental illness and psychiatry since Kraepelin’s death. But the legacy of his textbook and research agenda has continued to be of central importance to psychiatry to the present day, and however underfunded, psychiatry has been pursuing state-of-the-art research on mental health and mental illness with a good visibility. Psychiatric research needs to focus on a better understanding of the aetiopathology of mental disorders, to develop (bio)-markers that characterise pathophysiologically distinct subgroups and to implement mechanistically informed treatments. This will be crucial to make precision psychiatry a clinical reality. To make significant progress, there is a need to address relevant pathophysiological questions as well as a need to form teams of research specialists dedicated to answering these pressing questions. Once diagnostic and treatment targets are identified, clinical studies from single-case studies to large-scale implementation randomised controlled trials (RCTs) can bring these targets from the laboratory to the clinic. The final goal is to develop innovative personalised treatment strategies with a particular focus on conditions that are currently treatment-resistant. These include cognitive impairments and the so-called negative symptoms including anhedonia, avolition and lack of drive. There is no need for a pessimistic assessment of the progress achieved in the last 100 years; however, excellent research, as well as serendipity, is required to ensure transformative innovations. Both positive and negative findings need to be published and sufficient funding secured.
- Open Access
- 15 November 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1)
Metabolomic biomarkers of psychotic conversion in ultra-high-risk subjects: a pilot study
Psychosis is a psychiatric condition that can become a chronic and severe psychiatric disorder affecting more than 1% of the population. The ultra-high risk (UHR) patients have a transition rate to psychosis of 25% after three years. We aimed to identify circulating metabolomic biomarkers for psychotic conversion in UHR patients using nuclear magnetic resonance (NMR) spectroscopy. We used samples from 35 UHR patients: 14 converters (UHR-C) and 21 non-converters (UHR-NC) at inclusion from the ICAAR cohort. Serum samples were analysed using the high-throughput screening IVDr NMR method. R and SIMCA were used for statistical analysis. Several lipoprotein parameters related to HDL and LDL metabolism were downregulated in UHR-C compared to UHR-NC at the time of inclusion. The 3 best lipoproteins to predict psychotic conversion at baseline were H4A1, H4FC, and L4FC (Area under the Curve (AUC) values were 0.81, 0.81, and 0.78, respectively). These lipoproteins were also negatively correlated with PANSS scores. Our study is the first to use NMR technology to identify biomarkers to predict the risk of psychotic transition in UHR subjects. This pilot study found lipoprotein parameters related to ApoA-1 and HDL-cholesterol (subclass 4) as potential biomarkers. These results need to be replicated on a larger sample. This study highlights the importance of the detailed analysis of circulant lipoproteins related to the brain using NMR technology in early psychosis to identify biomarkers of psychotic transitions and perhaps to better understand the physiopathology of psychosis.
- 15 November 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1)
Open AccessMetabolomic biomarkers of psychotic conversion in ultra-high-risk subjects: a pilot study
Psychosis is a psychiatric condition that can become a chronic and severe psychiatric disorder affecting more than 1% of the population. The ultra-high risk (UHR) patients have a transition rate to psychosis of 25% after three years. We aimed to identify circulating metabolomic biomarkers for psychotic conversion in UHR patients using nuclear magnetic resonance (NMR) spectroscopy. We used samples from 35 UHR patients: 14 converters (UHR-C) and 21 non-converters (UHR-NC) at inclusion from the ICAAR cohort. Serum samples were analysed using the high-throughput screening IVDr NMR method. R and SIMCA were used for statistical analysis. Several lipoprotein parameters related to HDL and LDL metabolism were downregulated in UHR-C compared to UHR-NC at the time of inclusion. The 3 best lipoproteins to predict psychotic conversion at baseline were H4A1, H4FC, and L4FC (Area under the Curve (AUC) values were 0.81, 0.81, and 0.78, respectively). These lipoproteins were also negatively correlated with PANSS scores. Our study is the first to use NMR technology to identify biomarkers to predict the risk of psychotic transition in UHR subjects. This pilot study found lipoprotein parameters related to ApoA-1 and HDL-cholesterol (subclass 4) as potential biomarkers. These results need to be replicated on a larger sample. This study highlights the importance of the detailed analysis of circulant lipoproteins related to the brain using NMR technology in early psychosis to identify biomarkers of psychotic transitions and perhaps to better understand the physiopathology of psychosis.
- Open Access
- 8 September 2025
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (3) , 1137-1148
Clinical deep phenotyping of treatment response in schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study
Schizophrenia spectrum disorders (SSDs) exhibit a marked heterogeneity in clinical course and treatment outcomes. Some individuals achieve remission and recovery, whereas others experience repeated relapses and progressive deterioration in psychosocial functioning. This variability underscores the unmet clinical need for prognostic biomarkers to predict treatment outcomes and guide personalized care. Deep phenotyping with multimodal data integration holds promise for understanding this complexity and delivering clinically relevant predictive models of treatment response in SSDs. To address this need, we initiated the Clinical Deep Phenotyping of Treatment Response in Schizophrenia (CDP-STAR) study, a prospective, naturalistic, longitudinal observational study integrating comprehensive multimodal assessments. These include clinical phenotyping, magnetic resonance imaging (MRI), electroencephalography (EEG), retinal imaging, and extensive sampling of blood and cerebrospinal fluid (CSF) for multi-omics profiling. The study aims to externally validate promising biomarker candidates and elucidate the pathophysiological mechanisms underlying treatment outcomes. This innovative deep phenotyping framework integrates data across multiple critical domains, enabling external validation of potential biomarkers and the discovery of novel ones. Ultimately, the CDP-STAR study aims to yield mechanistic insights that advance precision psychiatry and inform clinical decision-making in SSDs.
- 8 September 2025
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 276 (3) , 1137-1148
Open AccessClinical deep phenotyping of treatment response in schizophrenia (CDP-STAR): design and methodology of a prospective multimodal observational study
Schizophrenia spectrum disorders (SSDs) exhibit a marked heterogeneity in clinical course and treatment outcomes. Some individuals achieve remission and recovery, whereas others experience repeated relapses and progressive deterioration in psychosocial functioning. This variability underscores the unmet clinical need for prognostic biomarkers to predict treatment outcomes and guide personalized care. Deep phenotyping with multimodal data integration holds promise for understanding this complexity and delivering clinically relevant predictive models of treatment response in SSDs. To address this need, we initiated the Clinical Deep Phenotyping of Treatment Response in Schizophrenia (CDP-STAR) study, a prospective, naturalistic, longitudinal observational study integrating comprehensive multimodal assessments. These include clinical phenotyping, magnetic resonance imaging (MRI), electroencephalography (EEG), retinal imaging, and extensive sampling of blood and cerebrospinal fluid (CSF) for multi-omics profiling. The study aims to externally validate promising biomarker candidates and elucidate the pathophysiological mechanisms underlying treatment outcomes. This innovative deep phenotyping framework integrates data across multiple critical domains, enabling external validation of potential biomarkers and the discovery of novel ones. Ultimately, the CDP-STAR study aims to yield mechanistic insights that advance precision psychiatry and inform clinical decision-making in SSDs.
- Open Access
- 16 August 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 287
iPSC-modelling reveals genetic associations and morphological alterations of oligodendrocytes in schizophrenia
There is strong evidence for a genetically driven neuronal contribution in schizophrenia (SCZ). Although imaging and postmortem studies also provide evidence for white matter alterations with implications of the oligodendroglial lineage in SCZ, it is unclear whether these disturbances are a secondary consequence of neuronal deficits or also, at least in parts, genetically driven and cell-autonomous. Using human induced pluripotent stem cells (hiPSCs) in combination with gene set enrichment analysis, we investigated the cellular impact of SCZ genetics on the oligodendroglial lineage. We performed unsupervised clustering analysis of hiPSC-differentiated neural cells including oligodendrocytes (iOLs) and their precursor cells (iOPCs) with corresponding human postmortem cell types from single-cell RNA sequencing (scRNAseq) data and conducted a comparative gene set enrichment analysis. Subsequently, we stratified individuals based on white matter alteration using diffusion tensor imaging (DTI) within a translational cohort (N = 112) and then explored the cellular effects of SCZ risk with hiPSC modelling in a subset of SCZ patients (N = 8) with disturbed white matter integrity and unaffected healthy controls (N = 7). hiPSC-iOPCs/iOLs expression profiles strongly correlated with human postmortem OPCs/OLs based on scRNAseq, and their transcriptional signatures were highly enriched in the genetic associations of SCZ. The cellular assessment of patient-derived iOPCs/iOLs revealed morphological alterations, including significantly increased branch length and elevated junction number in mature iOLs from SCZ. Moreover, transcriptomic profiling revealed a dysregulation in oligodendroglial cell signaling and proliferation. In sum, hiPSC-modelling shows an impact of SCZ genetics on dedicated features of the oligodendroglial lineage.
- 16 August 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 287
Open AccessiPSC-modelling reveals genetic associations and morphological alterations of oligodendrocytes in schizophrenia
There is strong evidence for a genetically driven neuronal contribution in schizophrenia (SCZ). Although imaging and postmortem studies also provide evidence for white matter alterations with implications of the oligodendroglial lineage in SCZ, it is unclear whether these disturbances are a secondary consequence of neuronal deficits or also, at least in parts, genetically driven and cell-autonomous. Using human induced pluripotent stem cells (hiPSCs) in combination with gene set enrichment analysis, we investigated the cellular impact of SCZ genetics on the oligodendroglial lineage. We performed unsupervised clustering analysis of hiPSC-differentiated neural cells including oligodendrocytes (iOLs) and their precursor cells (iOPCs) with corresponding human postmortem cell types from single-cell RNA sequencing (scRNAseq) data and conducted a comparative gene set enrichment analysis. Subsequently, we stratified individuals based on white matter alteration using diffusion tensor imaging (DTI) within a translational cohort (N = 112) and then explored the cellular effects of SCZ risk with hiPSC modelling in a subset of SCZ patients (N = 8) with disturbed white matter integrity and unaffected healthy controls (N = 7). hiPSC-iOPCs/iOLs expression profiles strongly correlated with human postmortem OPCs/OLs based on scRNAseq, and their transcriptional signatures were highly enriched in the genetic associations of SCZ. The cellular assessment of patient-derived iOPCs/iOLs revealed morphological alterations, including significantly increased branch length and elevated junction number in mature iOLs from SCZ. Moreover, transcriptomic profiling revealed a dysregulation in oligodendroglial cell signaling and proliferation. In sum, hiPSC-modelling shows an impact of SCZ genetics on dedicated features of the oligodendroglial lineage.
- Open Access
Cerebrospinal fluid proteomics reveals synaptic and immune dysregulation in treatment-resistant schizophrenia
IMPORTANCE: Treatment-resistant schizophrenia (TRS) affects around one-third of individuals with schizophrenia and is associated with substantial morbidity, mortality, and healthcare burden. Despite its impact, the pathophysiology of TRS remains poorly understood, and no validated biomarkers exist to predict or stratify treatment resistance and identify patients who may benefit from earlier second-line interventions. OBJECTIVE: To identify cerebrospinal fluid protein signatures associated with treatment-resistant schizophrenia using high-throughput immune-based proteomic profiling, and to characterize their biological relevance and evaluate their predictive potential. DESIGN, SETTING AND PARTICIPANTS: This cross-sectional study analyzed cerebrospinal fluid samples, collected between 2001 and 2024 during routine clinical practice in two centers, of 64 patients with treatment-resistant schizophrenia, and 84 sex-, age-, and center-matched non-treatment-resistant patients. Proteomic profiling was performed using Olink Explore HT, a highly sensitive, multiplexed proximity extension assay capable of quantifying up to 5,416 proteins. Univariate differential expression analysis, Gene Set Enrichment Analysis, and Support Vector Machine modelling were conducted to identify treatment-resistant schizophrenia-associated proteins, explore underlying biological mechanisms, and uncover predictive biomarker signatures. MAIN OUTCOMES AND MEASURES: Differentially expressed proteins, associated functional pathway enrichments, and classification performance of predictive models based on cerebrospinal fluid proteomics. RESULTS: 1,839 protein assays passed detection threshold in cerebrospinal fluid proteomic analysis using Olink Explore HT. 98 proteins were differentially expressed in individuals with treatment-resistant schizophrenia and 95 displayed consistent fold changes across both study centers. Gene Set Enrichment Analysis revealed that upregulated proteins were linked to immune-related pathways, while downregulated proteins were predominantly enriched in synapse-related processes, including glutamatergic signaling. Multivariate support vector machine modelling identified 64 proteins predictive of treatment-resistant schizophrenia, of which 63 overlapped with the differentially expressed proteins. CONCLUSIONS AND RELEVANCE: Cerebrospinal fluid proteomic profiling indicates activation of immune-related processes and synaptic dysfunction in treatment-resistant schizophrenia, supporting the hypothesis that it represents a neurobiologically distinct subtype of the disorder. The identified candidate biomarker signature may support the development of liquid biopsy-based diagnostic tools and guide targeted treatment strategies. Key Points: Question: Are there proteomic alterations in the cerebrospinal fluid (CSF) of patients with treatment-resistant schizophrenia (TRS)? Findings: Unbiased CSF proteomics identified 98 proteins dysregulated in TRS, implicating pathways of neuroinflammation and synaptic dysfunction. Machine-Learning Validation pinpointed protein features with the strongest predictive value for TRS, of which 63 overlapped with the differentially expressed proteins. Meaning: The intersection of univariate and multivariate results yields a prioritized panel of protein biomarkers with potential to distinguish TRS patients from those responsive to first-line antipsychotic therapy. The identified CSF-based proteomic signature reveals immune and synaptic alterations in TRS and may pave the way for early diagnostic tools and targeted interventions to alter its disease-course.
Open AccessCerebrospinal fluid proteomics reveals synaptic and immune dysregulation in treatment-resistant schizophrenia
IMPORTANCE: Treatment-resistant schizophrenia (TRS) affects around one-third of individuals with schizophrenia and is associated with substantial morbidity, mortality, and healthcare burden. Despite its impact, the pathophysiology of TRS remains poorly understood, and no validated biomarkers exist to predict or stratify treatment resistance and identify patients who may benefit from earlier second-line interventions. OBJECTIVE: To identify cerebrospinal fluid protein signatures associated with treatment-resistant schizophrenia using high-throughput immune-based proteomic profiling, and to characterize their biological relevance and evaluate their predictive potential. DESIGN, SETTING AND PARTICIPANTS: This cross-sectional study analyzed cerebrospinal fluid samples, collected between 2001 and 2024 during routine clinical practice in two centers, of 64 patients with treatment-resistant schizophrenia, and 84 sex-, age-, and center-matched non-treatment-resistant patients. Proteomic profiling was performed using Olink Explore HT, a highly sensitive, multiplexed proximity extension assay capable of quantifying up to 5,416 proteins. Univariate differential expression analysis, Gene Set Enrichment Analysis, and Support Vector Machine modelling were conducted to identify treatment-resistant schizophrenia-associated proteins, explore underlying biological mechanisms, and uncover predictive biomarker signatures. MAIN OUTCOMES AND MEASURES: Differentially expressed proteins, associated functional pathway enrichments, and classification performance of predictive models based on cerebrospinal fluid proteomics. RESULTS: 1,839 protein assays passed detection threshold in cerebrospinal fluid proteomic analysis using Olink Explore HT. 98 proteins were differentially expressed in individuals with treatment-resistant schizophrenia and 95 displayed consistent fold changes across both study centers. Gene Set Enrichment Analysis revealed that upregulated proteins were linked to immune-related pathways, while downregulated proteins were predominantly enriched in synapse-related processes, including glutamatergic signaling. Multivariate support vector machine modelling identified 64 proteins predictive of treatment-resistant schizophrenia, of which 63 overlapped with the differentially expressed proteins. CONCLUSIONS AND RELEVANCE: Cerebrospinal fluid proteomic profiling indicates activation of immune-related processes and synaptic dysfunction in treatment-resistant schizophrenia, supporting the hypothesis that it represents a neurobiologically distinct subtype of the disorder. The identified candidate biomarker signature may support the development of liquid biopsy-based diagnostic tools and guide targeted treatment strategies. Key Points: Question: Are there proteomic alterations in the cerebrospinal fluid (CSF) of patients with treatment-resistant schizophrenia (TRS)? Findings: Unbiased CSF proteomics identified 98 proteins dysregulated in TRS, implicating pathways of neuroinflammation and synaptic dysfunction. Machine-Learning Validation pinpointed protein features with the strongest predictive value for TRS, of which 63 overlapped with the differentially expressed proteins. Meaning: The intersection of univariate and multivariate results yields a prioritized panel of protein biomarkers with potential to distinguish TRS patients from those responsive to first-line antipsychotic therapy. The identified CSF-based proteomic signature reveals immune and synaptic alterations in TRS and may pave the way for early diagnostic tools and targeted interventions to alter its disease-course.
- Open Access
- 13 May 2025
- Published by Elsevier in Psychiatry Research
- Vol. 350, 116536
How childhood adversities shape minds and lives: An analysis across the affective-to-psychotic spectrum
- 13 May 2025
- Published by Elsevier in Psychiatry Research
- Vol. 350, 116536
Open AccessHow childhood adversities shape minds and lives: An analysis across the affective-to-psychotic spectrum
- Open Access
Development and validation of polygenic risk profiles of schizophrenia
Understanding the genetic architecture of schizophrenia (SCZ) is invaluable for the development of personalized treatment. In three independent cohorts, using an automated pipeline, we calculated 413 psychiatry-relevant polygenic scores. Using these scores, machine learning was applied to stratify SCZ patients into two biotypes in FinnGen (nSCZ=7486), and to validate these results in the PsyCourse Study (nSCZ=421) and Bari (nSCZ=531). While the two biotypes showed comparable polygenic SCZ risk, they were primarily distinguished by a greater predisposition for neuroticism, depression-related traits, and lower cognitive performance in Biotype 1. The genetic prediction of Biotype 1 was phenotypically characterized by an increased prevalence of SCZ and a more severe and complex clinical manifestation. This illustrates that the penetrance of genetic SCZ risk might partially depend on the predisposition for the aforementioned traits through pleiotropic variants. Our results provide novel, replicable insights into the genetic architecture of SCZ and might inform future personalized treatments.
Open AccessDevelopment and validation of polygenic risk profiles of schizophrenia
Understanding the genetic architecture of schizophrenia (SCZ) is invaluable for the development of personalized treatment. In three independent cohorts, using an automated pipeline, we calculated 413 psychiatry-relevant polygenic scores. Using these scores, machine learning was applied to stratify SCZ patients into two biotypes in FinnGen (nSCZ=7486), and to validate these results in the PsyCourse Study (nSCZ=421) and Bari (nSCZ=531). While the two biotypes showed comparable polygenic SCZ risk, they were primarily distinguished by a greater predisposition for neuroticism, depression-related traits, and lower cognitive performance in Biotype 1. The genetic prediction of Biotype 1 was phenotypically characterized by an increased prevalence of SCZ and a more severe and complex clinical manifestation. This illustrates that the penetrance of genetic SCZ risk might partially depend on the predisposition for the aforementioned traits through pleiotropic variants. Our results provide novel, replicable insights into the genetic architecture of SCZ and might inform future personalized treatments.
- 23 April 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (9) , 4364-4383
Integrative analysis of miRNA expression profiles reveals distinct and common molecular mechanisms underlying broad diagnostic groups of severe mental disorders
Micro RNAs (miRNAs) play a crucial role as regulators of various biological processes and have been implicated in the pathogenesis of mental disorders such as schizophrenia and bipolar disorders. In this study, we investigate the expression patterns of miRNAs in the PsyCourse Study (n = 1786), contrasting three broad diagnostic groups: Psychotic (Schizophrenia-spectrum disorders), Affective (Bipolar Disorder I, II and recurrent Depression), and neurotypic healthy individuals. Through comprehensive analyses, including differential miRNA expression, miRNA transcriptome-wide association study (TWAS), and predictive modelling, we identified multiple miRNAs unique to Psychotic and Affective groups as well as shared by both. Furthermore, we performed integrative analysis to identify the target genes of the dysregulated miRNAs and elucidate their potential roles in psychosis. Our findings reveal significant alterations of multiple miRNAs such as miR-584-3p and miR-99b-5p across the studied diagnostic groups, highlighting their role as molecular correlates. Additionally, the miRNA TWAS analysis discovered previously known and novel genetically dysregulated miRNAs confirming the relevance in the etiology of the diagnostic groups. Importantly, novel factors and putative molecular mechanisms underlying these groups were uncovered through the integration of miRNA-target gene interactions. This comprehensive investigation provides valuable insights into the molecular underpinnings of severe mental disorders, shedding light on the complex regulatory networks involving miRNAs.
- 23 April 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (9) , 4364-4383
Integrative analysis of miRNA expression profiles reveals distinct and common molecular mechanisms underlying broad diagnostic groups of severe mental disorders
Micro RNAs (miRNAs) play a crucial role as regulators of various biological processes and have been implicated in the pathogenesis of mental disorders such as schizophrenia and bipolar disorders. In this study, we investigate the expression patterns of miRNAs in the PsyCourse Study (n = 1786), contrasting three broad diagnostic groups: Psychotic (Schizophrenia-spectrum disorders), Affective (Bipolar Disorder I, II and recurrent Depression), and neurotypic healthy individuals. Through comprehensive analyses, including differential miRNA expression, miRNA transcriptome-wide association study (TWAS), and predictive modelling, we identified multiple miRNAs unique to Psychotic and Affective groups as well as shared by both. Furthermore, we performed integrative analysis to identify the target genes of the dysregulated miRNAs and elucidate their potential roles in psychosis. Our findings reveal significant alterations of multiple miRNAs such as miR-584-3p and miR-99b-5p across the studied diagnostic groups, highlighting their role as molecular correlates. Additionally, the miRNA TWAS analysis discovered previously known and novel genetically dysregulated miRNAs confirming the relevance in the etiology of the diagnostic groups. Importantly, novel factors and putative molecular mechanisms underlying these groups were uncovered through the integration of miRNA-target gene interactions. This comprehensive investigation provides valuable insights into the molecular underpinnings of severe mental disorders, shedding light on the complex regulatory networks involving miRNAs.